All relevant data are within the paper and its Supporting Information files.

1. Introduction {#sec005}
===============

Hepatocellular carcinoma (HCC) is the most common primary malignancy of the liver \[[@pone.0232449.ref001]\]. It represents the fifth most common cancer worldwide and the second cause of cancer mortality \[[@pone.0232449.ref002]\]. Sorafenib, an oral multikinase inhibitor (VEGFR- 1/2/3, PDGFR, Flt3, c-Kit, and Raf kinases), has been considered the standard of care for patients with advanced unresectable HCC since 2007 \[[@pone.0232449.ref003],[@pone.0232449.ref004]\]. In the literature, several clinical and biochemical factors have been described as predictive or prognostic markers in patients with HCC treated with Sorafenib, such as etiology \[[@pone.0232449.ref005]--[@pone.0232449.ref007]\], Child-Pugh status \[[@pone.0232449.ref008]\], Barcelona Clinic Liver Cancer (BCLC) \[[@pone.0232449.ref005]\], medical drugs \[[@pone.0232449.ref009],[@pone.0232449.ref010]\], Body Mass Index (BMI) \[[@pone.0232449.ref011]\], macroscopic vascular invasion (MVI) \[[@pone.0232449.ref005]\], Aspartate aminotransferase (AST) \[[@pone.0232449.ref012]\], Albumin-Bilirubin (ALBI) grade \[[@pone.0232449.ref013]\], Alpha-fetoprotein (AFP) \[[@pone.0232449.ref005],[@pone.0232449.ref014],[@pone.0232449.ref015]\], Lactate Dehydrogenase (LDH) \[[@pone.0232449.ref015],[@pone.0232449.ref016]\], Neutrophil-to-lymphocyte ratio (NLR) \[[@pone.0232449.ref005],[@pone.0232449.ref016],[@pone.0232449.ref017]\], Immune-inflammation index (SII) \[[@pone.0232449.ref017],[@pone.0232449.ref018]\], and drug-related adverse events (AE) \[[@pone.0232449.ref019],[@pone.0232449.ref020]\]. In addition, the pattern of progression \[[@pone.0232449.ref021]\] and the reason for Sorafenib discontinuation \[[@pone.0232449.ref022]\] have been reported to have a significant correlation with survival. Furthermore, biological parameters, as serum and plasma proteins \[[@pone.0232449.ref023]\], genetic markers \[[@pone.0232449.ref024]--[@pone.0232449.ref026]\], microRNAs \[[@pone.0232449.ref027]\], and tissue biomarkers \[[@pone.0232449.ref028]\] have been investigated. At the moment other potential new biomarkers are under exploration, as the so-called OMICS revolution, Radiomics, and Liquid Biopsy \[[@pone.0232449.ref029]\].None, of these factors has been validated \[[@pone.0232449.ref030]\] and they are not usually used in clinical practice to select patients in making clinical decisions.

In this context, the prognostic nutritional index (PNI), is a multiparametric indicator based on serum albumin and peripheral lymphocyte count \[[@pone.0232449.ref031]\], has shown to reflect both the immune-inflammatory and nutritional status of patients \[[@pone.0232449.ref032]\], even if in HCC it particularly reflects the liver disfunction underlying this cancer. Interestingly, the PNI has demonstrated to correlate with survival outcomes of patients with several gastrointestinal cancers \[[@pone.0232449.ref033],[@pone.0232449.ref034]\], including HCC \[[@pone.0232449.ref035]--[@pone.0232449.ref037]\] but not in advanced stage. \[[@pone.0232449.ref038]\].

In the present study, we have investigated the impact of the PNI index on survival outcomes in four independent cohorts of advanced HCC treated with sorafenib.

2. Materials and methods {#sec006}
========================

This multicentric Italian study was conducted on a training cohort of 194 HCC patients consecutively treated at Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori from 2007 to 2015. Three validation cohorts of HCC patients were consecutively recruited by the University of Bologna for the first cohort, a multicentric prospective study (INNOVATE study) \[[@pone.0232449.ref039]\] for the second cohort and from the University of Palermo and IOV Veneto of Padua for the third cohort.

Patients with histologically or radiologically (according to the American Association for the Study of Liver Diseases 2005 guidelines) proven advanced- or intermediate-stage (refractory or unsuitable for loco-regional therapies) HCC treated with sorafenib in real life were eligible for our analysis. Patients who had received previous systemic therapies were excluded. All patients received sorafenib according to standard schedule (400 mg bid continuously); dose reduction was applied as clinically indicated. Follow-up consisted of a CT/MRI scan every 8 weeks or as clinically indicated. Tumor response was evaluated by modified Response Evaluation Criteria in Solid Tumors (mRECIST) \[[@pone.0232449.ref043]\]. Treatment with sorafenib was continued until disease progression, unacceptable toxicity or death.

The study protocol was reviewed and approved by the local Ethics Committee (CEIIAV: comitato etico IRST IRCCS AVR and CE-AVEC: comitato etico Bologna). Study number IRST B041 protocol number 5482/v.1 intern code: L3P1192. Study number Bologna 098/2014/U/Oss. All patients provided written informed consent.

2.1 Statistical analysis {#sec007}
------------------------

This analysis aimed to examine the association between baseline PNI index and Overall Survival (OS) in patients with HCC treated with sorafenib.

Information on neutrophil and albumin from hematologic blood tests carried out at baseline (the day before the start of treatment) was collected.

The PNI was calculated as follows: 10 × serum albumin concentration (g/dL) + 0.005 × peripheral lymphocyte count (number/mm^2^) \[[@pone.0232449.ref034]\]. The cut-off point of the PNI was determined to be 31.3 by ROC analysis.

Categorical variables were compared with Fisher's exact test.

OS was defined as the time interval from the first day of treatment to the day of death or last follow-up visit. OS was estimated by the Kaplan-Meier method and curves were compared by the log-rank test. Unadjusted and adjusted hazard ratios (HRs) by baseline characteristics (AST, Age, and Sex) were calculated using the Cox proportional hazards model. The discrimination ability of the final model was assessed with Harrell's concordance index (C-index).

MedCalc package (MedCalc^®^ version 16.8.4) was used for statistical analysis.

3. Results {#sec008}
==========

Among the 194 Sorafenib-treated HCC patients of the training group, 168 (86.6%) were males and 26 (13.4%) were females, with a median age of 70 years (range 25--87). Seventy-nine patients (40.7%) had an ECOG 0. The underlying etiology of liver disease was hepatitis B virus (HBV) in 45 patients (25.2%), hepatitis C virus (HCV) in 107 patients (55.1%), alcohol in 8 patients (4.1%), metabolic syndrome in 16 patients (8.2%), others in 18 patients (9.3%). The Child-Pugh Class was A in 157 patients (80.9%) and B in 30 patients (15.6%). Other baseline clinicopathologic and laboratory characteristics are summarized in **[Table 1](#pone.0232449.t001){ref-type="table"}**.

10.1371/journal.pone.0232449.t001

###### Baseline characteristics of the training cohort.

![](pone.0232449.t001){#pone.0232449.t001g}

  Parameters                             N (%)
  -------------------------------------- -------------------
  **Age, years (median, range)**         70 (25--87)
  **Gender**                             
  Female                                 26 (13.4%)
  Male                                   168 (86.6%)
  **ECOG PS**                            
  0--1                                   87 (44.8%)
  ≥2                                     79 (40.7%)
  Unknown                                28 (14.5%)
  **Etiology**                           
  HCV                                    107 (55.2%)
  HBV                                    45 (23.2%)
  Metabolic syndrome                     16 (8.3%)
  Alcohol                                8 (4.1%)
  Others                                 18 (9.2%)
  **Child-Pugh**                         
  A                                      157 (80.9%)
  B                                      30 (15.5%)
  Unknown                                7 (3.6%)
  **BCLC Stage**                         
  B                                      39 (20.1%)
  C                                      127 (65.4%)
  Unknown                                28 (14.5%)
  **"Local" Treatment**                  
  Liver transplantation                  4 (2.0%)
  Radiofrequency                         29 (14.9%)
  TACE                                   73 (37.6%)
  **PNI**                                
  Low-group (\<31.3)                     20 (10.3%)
  High-group (≥31.3)                     174 (89.7%)
  **ALBI grade**                         
  0                                      0
  1                                      188 (98.0)
  2                                      4 (2.0)
  **Laboratory tests (median, range)**   
  Neutrophils, cells/μl                  3540 (290--11490)
  Lymphocytes, cells/μl                  1300 (210--3560)
  Platelets, cells/μl                    137 (44--462)
  Albumin, gr/dl                         3.6 (2.6--5.0)
  Alkaline Phosphatase, IU/L             144.5 (69--698)
  G-GT, IU/L                             162 (45--1102)
  AST, IU/L                              56 (13--177)
  ALT, IU/L                              46 (10--218)
  Bilirubin, gr/dl                       0.91 (0.3--3.86)
  AFP, ng/ml                             23 (0.8--50000)

**Abbreviations**. ECOG PS, eastern cooperative oncology group performance status; HCV, hepatitis C virus; HBV, hepatitis B virus; BCLC stage, Barcelona clinic liver center staging; Child-Pugh, Child-Turcotte-Pugh score; TACE, transarterial chemoembolization; PNI, prognostic nutritional index; G-GT, gamma-glutamyl transpeptidase; ALT, alanine aminotransaminase; AST, aspartate aminotransaminase; AFP, alpha-fetoprotein.

A total of 20 (10.3%) patients was categorized as the PNI-low group, while the remaining 174 (89.7%) patients as the PNI-high group.

Eighty-one (41.7%) patients had early AE, while 57 (29.4%) patients had late AE. The most frequent drug-related AEs were dermatologic toxicity and diarrhea.

The median progression-free survival (mPFS) was 3,8 months (95% CI, 3.1--6.4) and the median overall survival (mOS) was 12.4 (95% CI, 11.3--24.6).

3.1 Prognostic value of the PNI in the training cohort {#sec009}
------------------------------------------------------

At the univariate analysis for OS high PNI was associated with longer mOS (14.8 vs 6.8 months, HR 5.26; 95% CI,2.49--11.10; p\<0.0001) **([Fig 1](#pone.0232449.g001){ref-type="fig"}).** In addition, normal level of AST (\<1 ULN) was correlated with better prognosis (HR 0.45; 95% CI, 0.30--0.68; p = 0.0002). No other correlations were found, particularly neither ALBI grade nor Child-Pugh status nor BCLC class were associated with prognosis, maybe due to the small number of patients in the worst classes. Nevertheless, we observed a trend towards a worse prognosis for these patients (ALBI grade: HR 2.47; 95% CI: 0.41--14.8; p = 0.1085; Child-Pugh status: HR 1.45; 95% CI: 0.90--2.32; p = 0.1312; BCLC class: HR 1,37; 95% CI: 0.92--2.03; p = 0.1132).

![OS according to PNI (high- vs low-group) in the training cohort.](pone.0232449.g001){#pone.0232449.g001}

Following adjustment for clinical covariates positive in univariate analysis, multivariate analysis confirmed PNI-low (HR 2.98; 95% CI: 1.63--5.47; p = 0.0004), a normal level of AST (HR 0.33; 95% CI: 0.2--0.5; p = 0.0001), and age \>70 years (HR 0.54; 95% CI: 0.36--0.82; p\<0.0038) as independent prognostic factors for OS **([Table 2](#pone.0232449.t002){ref-type="table"}).**

10.1371/journal.pone.0232449.t002

###### Univariate and multivariate analysis in the training cohort.
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  ----------------------------------------------------------------------------------------------------------------------------------------
  Covariate                                  Univariate analysis   Multivariate analysis                                      
  ------------------------------------------ --------------------- ----------------------- -------------- ------ ------------ ------------
  **Sex (female vs male)**                   1.29                  0.77--2.16              0.3164         \-     \-           \-

  **Age (\>70 vs \<70)**                     0.98                  0.71--1.35              0,9295         0.54   0.36--0.82   **0,0038**

  **ECOG PS (\>0 vs 0)**                     1.34                  0.95--1.91              0.0985                             

  **ALBI grade (2 vs 1)**                    2.47                  0.41--14.8              0.1085                             

  **Etiology**                                                                                            \-     \-           \-

  HCV                                        1.00                                                                             

  HBV                                        1.04                  0.71--1.51                                                 

  NASH                                       0.93                  0.53--1.63                                                 

  Alcool                                     0.86                  0.40--1.83                                                 

  Others                                     1.41                  0.75--2.65              0.7398                             

  **PNI (\<31.3 vs \>31.3)**                 0,19                  0,09--0,4               **\<0.0001**   2.98   1.63--5.47   **0,0004**

  **AST (\>NV vs NV)**                       2.21                  1.46--3.35              **0.0002**     0.33   0.20--0.57   **0,0001**

  **NLR (\>3 vs \<3)**                       1,03                  0.73--1,44              0.8629         \-     \-           \-

  **BCLC (C vs B)**                          1.37                  0.92--2.03              0,1132         \-     \-           \-

  **Bilirubin (\>NV vs NV)**                 1,29                  0,88--1,90              0,1873                             

  **ALT (\>NV vs NV)**                       1.22                  0,84--1,87              0,2955                             

  **Child-Pugh (B vs A)**                    1.45                  0.90--2.32              0,1213                             

  **AFP (\>400 vs \<400)**                   1.27                  0,87--1,87              0,2084                             

  **Reason for sorafenib discontinuation**                                                                                    

  **Tumor progression vs. AE**\              1.27                  0.91--1.45              **0.163**                          
  Clinical decompensation\                                                                                                    
  Clinical decompensation                                                                                                     
  ----------------------------------------------------------------------------------------------------------------------------------------

**Abbreviations**. PNI, prognostic nutritional index; AST, aspartate aminotransaminase; NV, normal value; NLR, neutrophil-to-lymphocyte ratio; BCLC stage, Barcelona clinic liver center staging; ECOG PS, eastern cooperative oncology group performance status; ALT, alanine aminotransaminase; Child-Pugh, Child-Turcotte-Pugh score; AFP, alpha-fetoprotein; AE, adverse event.

Patients with a low PNI index showed a higher percentage of progression disease (PD) at the first CT re-evaluation respect to patients with a high PNI index (40% vs. 15% respectively, p = 0.04).

Next, we evaluated PNI index modifications during the early course of treatment. We estimated OS after stratifying patients into 3 groups according to PNI levels at baseline and after one month. The first group included patients with low (\<31.3)-low (\<31.3) levels of PNI index (11 patients), the second included those with high (\>31.3)-low (\<31.3) PNI index (36 patients) and the third included those with high (\>31.3)-high (\>31.3) PNI index (72 patients). No patients were classified as PNI low (\<31,3)-PNI high (\>31,3). Patients in the first group had a median OS of 7.7 months compared to 12.4 months for those in the second group and 15.1 months for those in the third group (p = 0.0029) (**[Fig 2](#pone.0232449.g002){ref-type="fig"}**).

![OS according to PNI value changes after a month of treatment with Sorafenib in the training cohort.](pone.0232449.g002){#pone.0232449.g002}

3.2 Validation cohorts {#sec010}
----------------------

A total of three external validation cohorts were considered for the analysis. 129 patients diagnosed with HCC were taken from the Bologna center database and made up the first validation cohort. Baseline clinical and laboratory characteristics are summarized in **[Table 3](#pone.0232449.t003){ref-type="table"}**. Globally, 104 (80.6%) patients were categorized as the PNI-high group, while the remaining 25 (19.4%) patients as the PNI-low group. Maintaining the same observations of the training cohort, patients with PNI-low had a mOS of 4.0 months, whereas patients with a PNI-high had a mOS of 10.9 months (HR 0.03; 95% CI 0.01--0.08, p\<0.0001). By performing the same multivariate analysis of the training cohort, PNI-low was found to be an independent prognostic factor for OS (HR 6.53; 95% CI 3.79--11.25, p\<0.0001) (**[Fig 3A](#pone.0232449.g003){ref-type="fig"}**). The model had a C-index of 0.78.

![OS according to PNI in the first validation cohort (A); second validation cohort (B) and third validation cohort (C).](pone.0232449.g003){#pone.0232449.g003}

10.1371/journal.pone.0232449.t003

###### Baseline characteristics of the first, second- and third-validation cohort.
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  ----------------------------------------------------------------------------------------------------
  Parameters                             N (%)                                    
  -------------------------------------- ------------------- -------------------- --------------------
  **Age, years (median, range)**         67 (37--85)         67 (24--84)          66.8 (24--85)

  **Gender**                                                                      

  Female                                 17 (13.2%)          12 (15.8%)           52 (19.6%)

  Male                                   112 (86.8%)         64 (84.2%)           213 (80.4%)

  **ECOG PS**                                                                     

  0--1                                   94 (72.8%)          75 (98.7%)           253 (94.5%)

  ≥2                                     35 (27.2%)          1 (1.3%)             11 (4.1%)

  Unknown                                0 (0%)              0 (0%)               1 (0.4%)

  **Etiology**                                                                    

  HCV                                    68 (52.7%)          26 (34.2%)           104 (39.2%)

  HBV                                    20 (15.5%)          8 (10.5%)            34 (12.8%)

  Metabolic syndrome                     41 (31.8%)          6 (7.9%)             17 (6.4%)

  Alcol                                  0 (0%)              6 (7.9%)             37 (13.9%)

  Other                                  0 (0%)              30 (39.5%)           73 (27.7%)

  **Child-Pugh**                                                                  

  A                                      121 (93.8%)         65 (85.5%)           238 (89.8)

  B                                      8 (6.2%)            11 (14.5%)           27 (10.2)\

  **BCLC Stage**                                                                  

  B                                      27 (21.0%)          20 (26.3%)           53 (20.0%)

  C                                      102 (79.0%)         56 (73.7%)           212 (80.0%)

  **"Local" Treatment**                                                           

  Liver transplantation                  45 (34.8%)          NA                   NA

  Radiofrequency                         23 (17.8%)          NA                   NA

  TACE                                   66 (51.1%)          NA                   NA

  **PNI**                                                                         

  Low-group (\<31.3)                     25 (19.4%)          15 (19.7%)           34 (12.8%)

  High-group (≥31.3)                     104 (80.6%)         61 (80.3%)           231 (87.2%)

  **Laboratory tests (median, range)**                                            

  Neutrophils, cells/μl                  3590 (750--10200)   4100 (730--600000)   4180 (1100--12740)

  Lymphocytes, cells/μl                  1130 (250--4800)    1505 (590--6850)     1300 (102--4250)

  Platelets, cells/μl                    138 (26--400)       NA                   123 (13--483)

  Albumin, gr/dl                         3.6 (2.7--5.0)      NA                   3.7 (2.6--5.3)

  Alkaline Phosphatase, IU/L             191 (44--1231)      NA                   NA

  G-GT, IU/L                             108 (17--1043)      NA                   NA

  AST, IU/L                              53 (9--334)         57 (13--238)         51 (19--300)

  ALT, IU/L                              41 (5--300)         43 (6--348)          NA

  Bilirubin, gr/dl                       0.94 (0.2--3.04)    0.81 (0.21--3.15)    NA

  AFP, ng/ml                             30 (1.0--60500)     44.1 (0.8-\>50000)   72.7 (1.1--457300)
  ----------------------------------------------------------------------------------------------------

**Abbreviations**. ECOG PS, eastern cooperative oncology group performance status; HCV, hepatitis C virus; HBV, hepatitis B virus; BCLC stage, Barcelona clinic liver center staging; Child-Pugh, Child-Turcotte-Pugh score; TACE, transarterial chemoembolization; NA, not available; PNI, prognostic nutritional index; G-GT, gamma-glutamyl transpeptidase; ALT, alanine aminotransaminase; AST, aspartate aminotransaminase; AFP, alpha-fetoprotein;

The participants in a second validation cohort were 76 patients collected in the Innovate STUDY database \[[@pone.0232449.ref042]\]. Baseline clinical and laboratory characteristics are summarized in **[Table 3](#pone.0232449.t003){ref-type="table"}**.

Globally, 61 (80.3%) patients were categorized as the PNI-high group, while the remaining 15 (19.7%) patients as the PNI-low group. Patients with PNI-low had a mOS of 3.9 months, whereas patients with a PNI-high had a mOS of 12.4 months (HR 0.1, 95% CI 0.04--0.31, p\<0.0001) (**[Fig 3B](#pone.0232449.g003){ref-type="fig"}**). By performing the same multivariate analysis of the training cohort, PNI-low was found to be an independent prognostic factor for OS (HR 2.98, 95% CI 1.25--7.08; p = 0.0135). The model had a C-index of 0.73.

The participants in a third validation cohort were 265 patients taken from Palermo and Padua centers. Baseline clinical and laboratory characteristics are summarized in **[Table 3](#pone.0232449.t003){ref-type="table"}.**

Overall, 231 (87.2%) patients were categorized as the PNI-high group, while the remaining 34 (12.8%) patients as the PNI-low group. Patients with PNI-low had a mOS of 7.1 months, whereas patients with a PNI-high had a mOS of 13.3 months (HR 0.47, 95% CI 0.28--0.78, p = 0.0037). By performing the same multivariate analysis of the training cohort, PNI-low was found to be an independent prognostic factor for OS (HR 1.94, 95% CI 1.22--4.58; p = 0.001) (**[Fig 3C](#pone.0232449.g003){ref-type="fig"}**). The model had a C-index of 0.77.

Multivariate analyses of the three validation cohorts are summarized in **[Table 4](#pone.0232449.t004){ref-type="table"}**.

10.1371/journal.pone.0232449.t004

###### Multivariate analysis in the first, second and third validation cohort.

![](pone.0232449.t004){#pone.0232449.t004g}

  Covariate        Multivariate analysis                                                                                     
  ---------------- ----------------------- ------------- -------------- ------ ------------ ------------ ------ ------------ ------------
  **PNI \<31.3**   6.53                    3.79--11.25   **\<0.0001**   2.98   1.25--7.08   **0.0135**   1.94   1.22--4.58   **0.0012**
  **AST**          0.81                    0.54--1.22    0.3326         0.91   0.44--1.89   0.8099       1.00   0.99--1.01   0.2494
  **Age**          0.77                    0.51--1.16    0.2189         1.43   0.73--2.80   0.2873       0.55   0.25--1.22   0.1435
  **Sex**          1.13                    0.63--2.03    0.6774         2.39   0.98--5.78   0.0529       0.77   0.33--1.80   0.5529

**Abbreviations**. PNI, prognostic nutritional index; AST, aspartate aminotransaminase.

4. Discussion {#sec011}
=============

In this large retrospective study totalling a number of 660 patients, including three independent validation cohorts of subjects, we demonstrated that the PNI is an independent predictor of survival.

PNI index is composed of only two parameters. This simplification of the index makes it more available and simpler for daily clinical practice respect others index evaluated by our and others groups \[[@pone.0232449.ref005],[@pone.0232449.ref008],[@pone.0232449.ref035]--[@pone.0232449.ref038]\].

The results of our analysis are in line with previous studies evaluating the prognostic role of this index. Particularly, Chan et al reported that the PNI predicts tumor recurrence in early-stage HCC after surgical resection \[[@pone.0232449.ref039]\]; it is also associated with survival of HCC patients after loco-regional or systemic therapy, as reported by Pinato et al \[[@pone.0232449.ref040]\]. Furthermore, a meta-analysis of eleven studies also proved that a low PNI is a poor prognostic factor for OS and disease-free survival (DFS) in HCC, whereas a high PNI is a favourable prognostic factor and is associated with better clinical predictors, such as lower AFP, lower recurrence rates, smaller tumor size, and earlier TNM tumor stage \[[@pone.0232449.ref041]\].

In the Japanese experience of Hatanaka et al \[[@pone.0232449.ref042]\], the PNI was a significant factor associated with the duration of Sorafenib therapy and the OS among pre-treatment factors in a cohort of patients treated with Sorafenib. No significant differences in terms of Sorafenib efficacy and serious adverse events rate were found between high- and low-PNI groups.

In keeping with the Japanese results, we showed the prognostic role of the PNI in a European population and we validated these results in three independent cohorts of patients with HCC treated with Sorafenib.

Several mechanisms could be put forward to explain how the PNI influences the survival of HCC patients, including those receiving sorafenib. First of all, the PNI, a combination of serum albumin and total lymphocyte count, reflects the link existing between immunity, inflammation, and nutrition in cancer, with their consequent potential prognostic implications. A low PNI may be caused by hypoalbuminemia and/or lymphocytopenia. In connection with the role of lymphocytopenia, it is well-known that T lymphocytes play an essential role in the immune and anti-cancer response and also in the biological behavior of HCC, such as initiation, proliferation, differentiation, and metastasis \[[@pone.0232449.ref043],[@pone.0232449.ref044]\]. In previous studies on HCC, it has been reported that the presence of more abundant tumor-infiltrating effector T lymphocytes (TILs) is associated with better outcomes after surgical resection \[[@pone.0232449.ref045]\] while a reduced number appeared related to higher tumor recurrence rates after liver transplantation \[[@pone.0232449.ref046]\]. Similar results were observed also in advanced HCC, where the count of CD8+T cells in TILs was lower in patients with metastatic disease than in those without \[[@pone.0232449.ref047]\] and the ability of specific subsets of T cells in HCC was claimed to be able to predict extrahepatic metastasis and prognosis \[[@pone.0232449.ref048],[@pone.0232449.ref049]\].

In connection with the role of hypoalbuminemia, albumin is a known prognostic factor in HCC, specifically included in staging systems like the Cancer of the Liver Italian Program (CLIP) score \[[@pone.0232449.ref050]\] or the ALBI grade \[[@pone.0232449.ref051]\] and in many other staging systems.

In this setting, albuminemia may be specifically influenced by three factors: 1) the liver dysfunction, usually related to the common underlying cirrhotic condition; 2) the nutritional status, including cancer cachexia; 3) the cancer-related inflammation. Furthermore, lower albumin levels were shown to be associated with increased risks of developing portal vein thrombosis in cirrhosis \[[@pone.0232449.ref052]\]. Whether similar effects may take place at a microvascular level leading to accelerated liver dysfunction remains a purely speculative hypothesis \[[@pone.0232449.ref053]\].

Interestingly, we were able to test and confirm in our training cohort not only that PNI level contributes to predicting survival when tested at baseline, but also when patients were subdivided into three groups according to the changes of PNI value over the first month of Sorafenib treatment, with the best OS observed in patients who could maintain high PNI levels in the first month of treatment.

Limitations of the present study was its retrospective nature and for this reason we didn't collected all clinical variables and the cohorts of the study were unbalance for clinical variables. Other limitations of the study was the absence of a predefined standard cut-off value of the PNI. However, the cut-off obtained in our training group was validated in all the three external series, but it could strongly be validated by a prospective study. Another important limitation of our study is the absence of a control arm not receiving sorafenib, making not possible to evaluate the predictive role of the index.

In conclusion, we proposed the PNI as an easy-to-use prognostic factor in patients with HCC treated with Sorafenib, including nutritional status, inflammation, and immunity in a single marker. It is also readily available and low-cost, and for these reasons, it could be implemented in clinical practice and useful in trial design in patients with HCC.

Supporting information {#sec012}
======================

###### 

(XLSX)

###### 

Click here for additional data file.

HCC

:   Hepatocellular carcinoma

BCLC

:   Barcelona Clinic Liver Cancer

BMI

:   Body Mass Index

MVI

:   macroscopic vascular invasion

ALBI

:   Albumin-Bilirubin

AFP

:   Alpha-fetoprotein

LDH

:   Lactate Dehydrogenase

NLR

:   neutrophil-to-lymphocyte ratio

SII

:   immune-inflammation index

AE

:   adverse events

PNI

:   prognostic nutritional index

ECOG

:   Eastern Cooperative Oncology Group

ALT

:   alanine aminotransferase

AST

:   aspartate aminotransferase

mRECIST

:   modified Response Evaluation Criteria in Solid Tumors

OS

:   Overall Survival

HBV

:   hepatitis B virus

HCV

:   hepatitis C virus

mPFS

:   median progression-free survival

PD

:   progression disease

HRs

:   Hazard ratios

DFS

:   disease-free survival

CLIP

:   Cancer of the Liver Italian Program

TACE

:   transarterial chemoembolization

G-GT

:   gamma-glutamyl transpeptidase
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Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE's publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised by the reviewers. In addition, in your revised manuscript you should clarly highlight and discuss the novelty and differential value of your present study in view of previous works from your laboratory, such as Gastrointest Tumors, 2019;6:71-80  [doi.org/10.1159/000501593](http://doi.org/10.1159/000501593) .​

Specifically, you should argue, if this is the case, tha separation of the data into more than one article has not compromised the robustness of the statistical analysis of you current data.

We would appreciate receiving your revised manuscript by May 23 2020 11:59PM. When you are ready to submit your revision, log on to <https://www.editorialmanager.com/pone/> and select the \'Submissions Needing Revision\' folder to locate your manuscript file.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter.

To enhance the reproducibility of your results, we recommend that if applicable you deposit your laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. For instructions see: <http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols>

Please include the following items when submitting your revised manuscript:

A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). This letter should be uploaded as separate file and labeled \'Response to Reviewers\'.A marked-up copy of your manuscript that highlights changes made to the original version. This file should be uploaded as separate file and labeled \'Revised Manuscript with Track Changes\'.An unmarked version of your revised paper without tracked changes. This file should be uploaded as separate file and labeled \'Manuscript\'.

Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out.

We look forward to receiving your revised manuscript.

Kind regards,

Matias A Avila, Ph.D.

Academic Editor

PLOS ONE

Journal Requirements:

When submitting your revision, we need you to address these additional requirements.

Please ensure that your manuscript meets PLOS ONE\'s style requirements, including those for file naming. The PLOS ONE style templates can be found at

<https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf> and

<https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf>

\[Note: HTML markup is below. Please do not edit.\]

Reviewers\' comments:

Reviewer\'s Responses to Questions

**Comments to the Author**

1\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer \#1: Partly

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

2\. Has the statistical analysis been performed appropriately and rigorously?

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

3\. Have the authors made all data underlying the findings in their manuscript fully available?

The [PLOS Data policy](http://www.plosone.org/static/policies.action#sharing) requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.

Reviewer \#1: Yes

Reviewer \#2: No

\*\*\*\*\*\*\*\*\*\*

4\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#1: No

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

5\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#1: The Authors report the results of a retrospective study aimed to investigate the role of the prognostic nutritional index (PNI) on survival in patients with advanced hepatocellular carcinoma (HCC) treated with sorafenib. The topic is of interest considering the expanding landscape of treatment options for advanced HCC and the need to identify predictive and prognostic markers that can be of help in selecting patients to be treated with the available drugs. However, the retrospective nature of the study and the lack of a validated cutoff value for the PNI limit the robustness of the results.

The following comments should be addressed.

General comment

1\. The English language should be revised

Major comments:

1\. Introduction, page 4: Among the prognostic factors the Authors should mention the pattern of progression and the reason for sorafenib discontinuation as published by Reig M et al and Iavarone M et al, respectively (Hepatology 2013; Hepatology 2015). These factors should be included in the analyses

2\. Results, Prognostic and predictive value of the PNI in training cohort: Did the Authors evaluate the predictive role of PNI or only the prognostic role? In the methods they stated that both have been assessed but no results are available for the predictive role. This aspect should be clarified and discussed in the discussion

3\. Results, Validation cohorts: Baseline characteristics are partly different (e.g., ECOG PS, etiology) or missing (e.g., ALBI grade) in the validation cohorts. Did the Authors consider this factor in their analysis? This point should be also discussed in the discussion among the limitations of the study

4\. References: The number of references from the same Authors should be reduced and references from other groups should be added

Minor comment:

1\. References: Ref \#1 should be replaced with a more recent paper

Reviewer \#2: I read with interest the manuscript by Caputo et al. on the role of PNI to predict survival in advanced hepatocellular carcinoma treated with Sorafenib. Authors define the optimal cut-off of PNI independently associated with survival in a training cohort, and validate the finding in two external validation cohorts.

I have only the following minor points:

1\) It was surprising to me seeing that, in the training cohort, neither ALBI grade nor Child-Pugh class nor BCLC class were associated with prognosis at the univariate analysis. It is probably due to relatively small number of patients in the worst classes. Do Authors have any other explication for this? In any case, I think this should be properly acknowledged and discussed.

2\) In the Abstract, Results, the median OS of patients with low and high PNI has been inverted.

3\) In The Methods, Authors state, among the eligibility criteria, there was a Child-Pugh liver class A. However, subsequently, it is clearly reported that also Child-Pugh B patients have been enrolled in the 3 cohorts.

\*\*\*\*\*\*\*\*\*\*

6\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#1: No

Reviewer \#2: No

\[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link \"View Attachments\". If this link does not appear, there are no attachment files to be viewed.\]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, <https://pacev2.apexcovantage.com/>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at <figures@plos.org>. Please note that Supporting Information files do not need this step.

10.1371/journal.pone.0232449.r002

Author response to Decision Letter 0

14 Apr 2020

Editor comment: In your revised manuscript you should clarly highlight and discuss the novelty and differential value of your present study in view of previous works from your laboratory, such as Gastrointest Tumors, 2019;6:71-80 [doi.org/10.1159/000501593](http://doi.org/10.1159/000501593)

REPLY: This study was different respect others our works because we evaluated here a simpler index than the previous. For example, RAPID index was composed about neutrophil, lymphocyte count, LDH and AFP, different PNI was com posed only by lymphocyte count and albumin. This simplification of the index makes it more available and simpler for daily clinical practice. Furthermore, we have increase the number and cohorts of patients than the previous studies. We have added this points in the discussion.

Reviewer \#1: The Authors report the results of a retrospective study aimed to investigate the role of the prognostic nutritional index (PNI) on survival in patients with advanced hepatocellular carcinoma (HCC) treated with sorafenib. The topic is of interest considering the expanding landscape of treatment options for advanced HCC and the need to identify predictive and prognostic markers that can be of help in selecting patients to be treated with the available drugs. However, the retrospective nature of the study and the lack of a validated cutoff value for the PNI limit the robustness of the results.

The following comments should be addressed.

General comment

1\. The English language should be revised

REPLY: We have improved the English language of the paper

Major comments:

1\. Introduction, page 4: Among the prognostic factors the Authors should mention the pattern of progression and the reason for sorafenib discontinuation as published by Reig M et al and Iavarone M et al, respectively (Hepatology 2013; Hepatology 2015). These factors should be included in the analyses

REPLY: WE have added in the introduction these two papers. We have performed the analysis about the reason for sorafenib discontinuation. Unfortunately, we didn't have collected data about Pattern of progression for this reason the analyzes could not be performed. We have added this point in the limitation section.

2\. Results, Prognostic and predictive value of the PNI in training cohort: Did the Authors evaluate the predictive role of PNI or only the prognostic role? In the methods they stated that both have been assessed but no results are available for the predictive role. This aspect should be clarified and discussed in the discussion

REPLY: We very thank the reviewer for this point. In absence of control arm is not possible to definite the prognostic role for this reason we have delete the sentence in the methods. We have added this point in the discussion.

3\. Results, Validation cohorts: Baseline characteristics are partly different (e.g., ECOG PS, etiology) or missing (e.g., ALBI grade) in the validation cohorts. Did the Authors consider this factor in their analysis? This point should be also discussed in the discussion among the limitations of the study

REPLY: WE completely agree with the reviewer for this point. We have added it in the limitation section.

4\. References: The number of references from the same Authors should be reduced and references from other groups should be added

REPLY: We have reduced our references.

Minor comment:

1\. References: Ref \#1 should be replaced with a more recent paper

REPLY: We have changed the reference 1.

Reviewer \#2: I read with interest the manuscript by Caputo et al. on the role of PNI to predict survival in advanced hepatocellular carcinoma treated with Sorafenib. Authors define the optimal cut-off of PNI independently associated with survival in a training cohort, and validate the finding in two external validation cohorts.

I have only the following minor points:

1\) It was surprising to me seeing that, in the training cohort, neither ALBI grade nor Child-Pugh class nor BCLC class were associated with prognosis at the univariate analysis. It is probably due to relatively small number of patients in the worst classes. Do Authors have any other explication for this? In any case, I think this should be properly acknowledged and discussed.

REPLY: we observed a trend towards a worse prognosis for these patients. We agree with the reviewer that it was a consequence of a small number of patients. We have added this point in the result.

2\) In the Abstract, Results, the median OS of patients with low and high PNI has been inverted.

REPLY: We very thank the reviewer for this point.

3\) In The Methods, Authors state, among the eligibility criteria, there was a Child-Pugh liver class A. However, subsequently, it is clearly reported that also Child-Pugh B patients have been enrolled in the 3 cohorts.

REPLY: Yes, we completely agree with the reviewer, we enrolled patients in real life. We have rewritten eligibility criteria of the study.
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PONE-D-20-08153R1

Dear Dr. Casadei Gardini,

We are pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it complies with all outstanding technical requirements.

Within one week, you will receive an e-mail containing information on the amendments required prior to publication. When all required modifications have been addressed, you will receive a formal acceptance letter and your manuscript will proceed to our production department and be scheduled for publication.

Shortly after the formal acceptance letter is sent, an invoice for payment will follow. To ensure an efficient production and billing process, please log into Editorial Manager at <https://www.editorialmanager.com/pone/>, click the \"Update My Information\" link at the top of the page, and update your user information. If you have any billing related questions, please contact our Author Billing department directly at <authorbilling@plos.org>.

If your institution or institutions have a press office, please notify them about your upcoming paper to enable them to help maximize its impact. If they will be preparing press materials for this manuscript, you must inform our press team as soon as possible and no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact <onepress@plos.org>.

With kind regards,

Matias A Avila, Ph.D.

Academic Editor

PLOS ONE
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THE ROLE OF PNI TO PREDICT SURVIVAL IN ADVANCED HEPATOCELLULAR CARCINOMA TREATED WITH SORAFENIB

Dear Dr. Casadei-Gardini:

I am pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please notify them about your upcoming paper at this point, to enable them to help maximize its impact. If they will be preparing press materials for this manuscript, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact <onepress@plos.org>.

For any other questions or concerns, please email <plosone@plos.org>.

Thank you for submitting your work to PLOS ONE.

With kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr Matias A Avila

Academic Editor

PLOS ONE

[^1]: **Competing Interests:**The authors have declared that no competing interests exist.
